|
|
|
The John Curtin School's vision
for the future
- continuing excellence in fields of biomedical
science including bioinformatics, functional genomics, immunity, neuroscience
and structural biology
- understanding and providing treatments for
diseases like cancer, HIV/AIDS, diabetes, asthma and high blood pressure
|
 |
What's on this week at JCSMR!
| News & Events |  Scientific Achievement Award
Professor Phil Board, Leader of the Molecular Genetics Group and Head of the Structural Biology Program, recently received a Scientific Achievement Award from the International Society for the study of Xenobiotics. The award was presented at an Asia/Pacific Regional Conference in Bangkok. Professor Board then presented a Plenary Lecture on his work on glutathione transferases. The Australian National University acknowledges the financial contributions made by the ACT Government and the Australian Commonwealth Government towards the construction of the new John Curtin School of Medical Research building.
Previous news and Seminar Program
|
| Research Snapshot | >> |  Molecular Genetics Laboratory
There is considerable genetic variation between individuals that determines their capacity to metabolize and respond to therapeutic drugs. Some individuals metabolize certain drugs at such a high rate that “normal” doses are ineffective. In contrast others may metabolize drugs at a slow rate and suffer higher toxicity. This genetic variation in drug metabolism also modifies susceptibility to environmentally derived chemicals that can cause cancer or other disorders such as Parkinsons’s disease. Understanding this variation in individuals will allow the personalized prescription of therapeutic drugs at optimum levels and will lower the chances of adverse drug reactions. |
|
